{"log_id": 85868730028642124, "direction": 0, "words_result_num": 42, "words_result": [{"probability": {"variance": 0.007405, "average": 0.962407, "min": 0.751706}, "location": {"width": 129, "top": 171, "height": 26, "left": 163}, "words": "【药代动力学】"}, {"probability": {"variance": 0, "average": 0.999717, "min": 0.999524}, "location": {"width": 44, "top": 218, "height": 24, "left": 157}, "words": "吸收"}, {"probability": {"variance": 0, "average": 0.982002, "min": 0.982002}, "location": {"width": 28, "top": 212, "height": 26, "left": 1158}, "words": "周"}, {"probability": {"variance": 0.001365, "average": 0.989163, "min": 0.764354}, "location": {"width": 850, "top": 256, "height": 29, "left": 199}, "words": "口服单剂量克唑替尼,平均4~6小时克唑替尼的吸收达到峰值。每日服用250mg克唑替尼两次"}, {"probability": {"variance": 0.004368, "average": 0.981845, "min": 0.548254}, "location": {"width": 907, "top": 285, "height": 27, "left": 161}, "words": "15天内可达并保持稳态血药浓度,平均累积率为4.8。当剂量超出每日两次、每次200~300mg的剂量"}, {"probability": {"variance": 0.001691, "average": 0.985126, "min": 0.797756}, "location": {"width": 640, "top": 311, "height": 29, "left": 158}, "words": "范围,稳态系统药物暴露(Cmm和AUC)的增加略高于剂量的增加比例"}, {"probability": {"variance": 0.001099, "average": 0.987457, "min": 0.836342}, "location": {"width": 778, "top": 356, "height": 27, "left": 198}, "words": "单剂量口服给药250mg后,克唑替尼的平均绝对生物利用度为43%(范围:32%~6%"}, {"probability": {"variance": 0.007748, "average": 0.972973, "min": 0.508736}, "location": {"width": 874, "top": 399, "height": 28, "left": 198}, "words": "高脂膳食可使克唑替尼的 Aucinf和Cmax降低约14%。克唑替尼与食物同服或不同服均可。[参见"}, {"probability": {"variance": 0.001318, "average": 0.973045, "min": 0.91094}, "location": {"width": 85, "top": 429, "height": 25, "left": 161}, "words": "用法用量"}, {"probability": {"variance": 1e-06, "average": 0.999009, "min": 0.998038}, "location": {"width": 46, "top": 471, "height": 26, "left": 157}, "words": "分布"}, {"probability": {"variance": 0.000865, "average": 0.992626, "min": 0.79896}, "location": {"width": 865, "top": 513, "height": 26, "left": 205}, "words": "静脉注射50mg克唑替尼,药物几何平均分布容积(Vss)为1772升,说明药物自血浆广泛分布"}, {"probability": {"variance": 4.8e-05, "average": 0.995403, "min": 0.98347}, "location": {"width": 83, "top": 542, "height": 23, "left": 159}, "words": "至组织内"}, {"probability": {"variance": 0.001155, "average": 0.989842, "min": 0.80267}, "location": {"width": 873, "top": 582, "height": 27, "left": 198}, "words": "在体外克唑替尼与人体血浆蛋白结合率为91%,与药物浓度无关。体外研究表明克唑替尼为P-糖"}, {"probability": {"variance": 0.023947, "average": 0.923647, "min": 0.474559}, "location": {"width": 440, "top": 610, "height": 34, "left": 159}, "words": "蛋白(P-Bp)的底物。血液-血浆浓度比率约为1。"}, {"probability": {"variance": 0, "average": 0.999643, "min": 0.999521}, "location": {"width": 42, "top": 655, "height": 24, "left": 160}, "words": "代谢"}, {"probability": {"variance": 0.000154, "average": 0.993673, "min": 0.932505}, "location": {"width": 874, "top": 695, "height": 27, "left": 199}, "words": "体外研究表明参与克唑替尼代谢消除的主要酶是CYP3A4/5。克唑替尼在人体的主要代谢途径是哌"}, {"probability": {"variance": 0.00743, "average": 0.974962, "min": 0.489932}, "location": {"width": 778, "top": 725, "height": 25, "left": 158}, "words": "啶环氧化得到克唑替尼酰胺和O-脱羟产物,并在随后的第二步中0-脱羟产物形成共轭"}, {"probability": {"variance": 0.000504, "average": 0.99164, "min": 0.874454}, "location": {"width": 654, "top": 766, "height": 26, "left": 200}, "words": "人肝微粒体的体外研究表明,克唑替尼是一种时间依赖性CYP3A抑制剂"}, {"probability": {"variance": 0, "average": 0.999198, "min": 0.99853}, "location": {"width": 45, "top": 810, "height": 25, "left": 158}, "words": "清除"}, {"probability": {"variance": 0.002052, "average": 0.983952, "min": 0.81096}, "location": {"width": 471, "top": 851, "height": 26, "left": 200}, "words": "克唑替尼单剂量给药后,表观终末半衰期为42小时"}, {"probability": {"variance": 0.001765, "average": 0.991376, "min": 0.717417}, "location": {"width": 874, "top": 892, "height": 28, "left": 200}, "words": "健康志愿者在服用单剂量250mg放射物标记的克唑替尼后,在其粪便和尿液中分别发现给药剂量"}, {"probability": {"variance": 0.006221, "average": 0.979251, "min": 0.458762}, "location": {"width": 895, "top": 921, "height": 25, "left": 161}, "words": "63%和22%的放射物标记的克唑替尼。粪便与尿液中克唑替尼原型药物分别约占给药剂量53%和2.3%"}, {"probability": {"variance": 0.005515, "average": 0.977963, "min": 0.57628}, "location": {"width": 874, "top": 962, "height": 28, "left": 200}, "words": "克唑替尼250mg每日两次给药后在稳态时的平均表观清除率(CU/F)(60升/小时)低于单剂量"}, {"probability": {"variance": 0.006668, "average": 0.981323, "min": 0.454341}, "location": {"width": 823, "top": 991, "height": 26, "left": 161}, "words": "20mg口服给药后的(100升/小时),可能归因于克唑替尼多次给药后CYP3A的自动抑制"}, {"probability": {"variance": 0, "average": 0.999474, "min": 0.998745}, "location": {"width": 127, "top": 1033, "height": 26, "left": 159}, "words": "药物相互作用"}, {"probability": {"variance": 0.037428, "average": 0.803262, "min": 0.513008}, "location": {"width": 153, "top": 1027, "height": 61, "left": 724}, "words": "袋广东余"}, {"probability": {"variance": 0.000127, "average": 0.990089, "min": 0.964297}, "location": {"width": 301, "top": 1075, "height": 27, "left": 164}, "words": "克唑替尼与CYP3A底物合并用药"}, {"probability": {"variance": 0.005093, "average": 0.984319, "min": 0.620711}, "location": {"width": 546, "top": 1118, "height": 26, "left": 201}, "words": "克唑替尼为CYP3A体外和体内的抑制剂。癌症患者每两次"}, {"probability": {"variance": 0.031616, "average": 0.903301, "min": 0.489024}, "location": {"width": 224, "top": 1120, "height": 30, "left": 852}, "words": "克唑带品250mg,连续服"}, {"probability": {"variance": 5e-06, "average": 0.998384, "min": 0.991245}, "location": {"width": 626, "top": 1146, "height": 27, "left": 159}, "words": "用28天后,测得合并用药的药时曲线下面积为单独口服咪唑仑的3"}, {"probability": {"variance": 0, "average": 0.748732, "min": 0.748732}, "location": {"width": 120, "top": 1145, "height": 85, "left": 780}, "words": "但"}, {"probability": {"variance": 2.3e-05, "average": 0.993671, "min": 0.98571}, "location": {"width": 151, "top": 1148, "height": 23, "left": 924}, "words": "唑替尼是CYP3A"}, {"probability": {"variance": 0.001574, "average": 0.98482, "min": 0.844654}, "location": {"width": 349, "top": 1174, "height": 26, "left": 159}, "words": "的一种中度抑制剂[参见药物相互作用"}, {"probability": {"variance": 0.000515, "average": 0.988028, "min": 0.92103}, "location": {"width": 323, "top": 1215, "height": 26, "left": 163}, "words": "克唑替尼与CYP3A抑制剂合并用药"}, {"probability": {"variance": 0.005178, "average": 0.980335, "min": 0.507756}, "location": {"width": 874, "top": 1258, "height": 27, "left": 202}, "words": "克挫替尼单剂量口服150mg,合并强CYP3A抑制剂酮康唑(200mg,每日两次),可引起克唑替"}, {"probability": {"variance": 0.0157, "average": 0.958362, "min": 0.173993}, "location": {"width": 897, "top": 1285, "height": 28, "left": 159}, "words": "尼系统药物暴露量增加,且克唑替尼的 Aucinf和Cmax值分别为单独服用克唑替尼的约3.2倍和1.4倍"}, {"probability": {"variance": 0.018836, "average": 0.954785, "min": 0.398626}, "location": {"width": 811, "top": 1314, "height": 34, "left": 159}, "words": "但是目前尚未确立CYP3A抑制剂对稳态克唑替尼暴露量影响的大小【参见药物相"}, {"probability": {"variance": 0.001665, "average": 0.982062, "min": 0.835162}, "location": {"width": 322, "top": 1356, "height": 26, "left": 164}, "words": "克唑替尼与CYP3A诱导剂合并用药"}, {"probability": {"variance": 0.011806, "average": 0.964607, "min": 0.442145}, "location": {"width": 696, "top": 1398, "height": 30, "left": 202}, "words": "克唑替尼单剂量口服250mg,合并服用CYP3A强诱导剂利福平(600mgr每"}, {"probability": {"variance": 0.004633, "average": 0.965458, "min": 0.711995}, "location": {"width": 729, "top": 1422, "height": 31, "left": 160}, "words": "的AUCm和Cmax与单独服用克唑替尼相比分别降低82%和69%。但是尚未确立"}, {"probability": {"variance": 0.011183, "average": 0.964652, "min": 0.6062}, "location": {"width": 483, "top": 1454, "height": 26, "left": 160}, "words": "态克唑替尼暴露量的影响的大小/参见药物相互作用"}, {"probability": {"variance": 0.001944, "average": 0.9754, "min": 0.855217}, "location": {"width": 251, "top": 1496, "height": 27, "left": 165}, "words": "克唑替尼与抗酸剂合并用药"}], "language": 3}